EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
EyePoint Pharmaceuticals (NASDAQ: EYPT), a pharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, has scheduled its first quarter 2025 financial results announcement for May 7, 2025.
The company will host a conference call and live webcast at 8:30 a.m. ET to discuss Q1 2025 financial performance and recent corporate developments. Interested participants can register for the audio conference through a provided link, while a live webcast will be accessible through the Investors section of EyePoint's website. A replay of the webcast will be made available on the corporate website after the call concludes.
EyePoint Pharmaceuticals (NASDAQ: EYPT), un'azienda farmaceutica specializzata nello sviluppo di terapie innovative per gravi malattie retiniche, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 7 maggio 2025.
L'azienda terrà una conference call e una diretta webcast alle 8:30 a.m. ET per discutere le performance finanziarie del primo trimestre 2025 e gli ultimi sviluppi aziendali. Gli interessati possono registrarsi per la conferenza audio tramite un link fornito, mentre la diretta webcast sarà disponibile nella sezione Investitori del sito web di EyePoint. Una replica della webcast sarà accessibile sul sito aziendale dopo la conclusione della chiamata.
EyePoint Pharmaceuticals (NASDAQ: EYPT), una compañía farmacéutica centrada en el desarrollo de terapias innovadoras para enfermedades retinianas graves, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 7 de mayo de 2025.
La empresa realizará una llamada conferencia y una transmisión en vivo a las 8:30 a.m. ET para discutir el desempeño financiero del primer trimestre de 2025 y los recientes desarrollos corporativos. Los interesados pueden registrarse para la conferencia de audio a través de un enlace proporcionado, mientras que la transmisión en vivo estará disponible en la sección de Inversores del sitio web de EyePoint. Una repetición de la transmisión estará disponible en el sitio web corporativo después de la llamada.
EyePoint Pharmaceuticals (NASDAQ: EYPT)는 중증 망막 질환을 위한 혁신적인 치료법 개발에 주력하는 제약사로, 2025년 1분기 재무 결과 발표를 2025년 5월 7일로 예정했습니다.
회사는 2025년 1분기 재무 실적과 최근 기업 동향을 논의하기 위해 동부 시간 기준 오전 8시 30분에 컨퍼런스 콜과 라이브 웹캐스트를 진행할 예정입니다. 관심 있는 참가자는 제공된 링크를 통해 오디오 컨퍼런스에 등록할 수 있으며, 라이브 웹캐스트는 EyePoint 웹사이트의 투자자 섹션에서 시청할 수 있습니다. 콜 종료 후 웹캐스트 재방송도 회사 웹사이트에서 제공됩니다.
EyePoint Pharmaceuticals (NASDAQ : EYPT), une société pharmaceutique spécialisée dans le développement de traitements innovants pour les maladies rétiniennes graves, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 7 mai 2025.
L'entreprise organisera une conférence téléphonique et une diffusion en direct à 8h30 ET pour discuter des performances financières du premier trimestre 2025 et des récents développements corporatifs. Les participants intéressés peuvent s'inscrire à la conférence audio via un lien fourni, tandis qu'une diffusion en direct sera accessible dans la section Investisseurs du site web d'EyePoint. Un replay de la diffusion sera disponible sur le site corporate après la fin de l'appel.
EyePoint Pharmaceuticals (NASDAQ: EYPT), ein Pharmaunternehmen, das sich auf die Entwicklung innovativer Therapien für schwere Netzhauterkrankungen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 7. Mai 2025 geplant.
Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und einen Live-Webcast abhalten, um die Finanzergebnisse des ersten Quartals 2025 sowie aktuelle Unternehmensentwicklungen zu besprechen. Interessierte Teilnehmer können sich über einen bereitgestellten Link für die Audiokonferenz anmelden, während der Live-Webcast im Bereich Investoren auf der Website von EyePoint verfügbar sein wird. Eine Aufzeichnung des Webcasts wird nach der Telefonkonferenz auf der Unternehmenswebsite bereitgestellt.
- Company maintains active investor relations with regular quarterly updates
- Demonstrates transparency through scheduled earnings calls and webcasts
- None.
WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and highlight recent corporate developments.
To access the live conference call, please register using the audio conference link: https://register-conf.media-server.com/register/BI0695874f15d442e59e2fb362d4491cac. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States and recently completed a Phase 2 clinical trial in diabetic macular edema (DME).
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint is headquartered in Watertown, Massachusetts, and operates a commercial-ready manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
When will EyePoint (EYPT) release Q1 2025 earnings?
How can investors join EyePoint's Q1 2025 earnings call?
Will EyePoint's Q1 2025 earnings call be available for replay?
What will EyePoint cover in their May 7 earnings call?
What time does EYPT's Q1 2025 earnings webcast start?
